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BACKGROUND: It has recently been shown that soluble
interleukin-6  receptor  (sIL-6R) alone or  complexed
with interleukin (IL)-6, besides their regulatory role
in  a  wide  variety  of  both  normal  and  abnormal
biologic  reactions  mediated  by  IL-6,  could  be  an
effective stimulator of the cell function.
Aims:  The  key  question  of  the  present  study  is
whether the sIL-6Ra or sIL-6R with IL-6 released by
polymorphonuclear leukocytes (PMN) can influence
cytokine  secretion  such  as  tumor  necrosis factor-a
(TNF-a)  by  peripheral  blood  mononuclear  cells
(PBMC),  which  together  with  PMN  develop  the
inflammatory and immune response of a host.
Methods: Cells were isolated from heparinized whole
blood of healthy persons. The PMN were cultured for
1h at 37°C in 5% CO2. After incubation, the culture
supernatant of PMN was removed and was added to
PBMC. The PBMC were cultured for 1h at 37°C in the
same  conditions.  In  the  culture  supernatants  and
lysates of PMN, we examined the concentrations of
sIL-6R  by  enzyme-linked  immunosorbent  assay
(ELISA).  TNF-a was  measured  at  both  protein  and
mRNA  levels.  Protein  levels  were  determined  by
ELISA.  To  examine  TNF-a mRNA  expression,  we
isolated mRNA from PBMC after culture, using TRIZOL
Reagent.  The  quantity  of  mRNA  TNF-a was  deter-
mined by the Quantikine mRNA assay.
Results and conclusion: The results obtained revealed
that  sIL-6R  with  IL-6  secreted  by  PMN  may  play  a
regulatory role in the immune response by modulat-
ing  the  TNF-a expression  and  its  production  by
PBMC. This may have a significant influence on an
early phase of the inflammation and other reactions
mediated by TNF-a.
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Introduction
Polymorphonuclear leukocytes (PMN), abundant cells
of  an  early  phase  of  inflammation,  have  ability  to
release a wide range of cytokines and their soluble
receptors,  which  influence  the  host’s  non-specific
and specific immune response.1 Interleukin (IL)-6 and
its soluble receptors, soluble interleukin-6 receptor a
(sIL-6Ra)  and  sgp130,  among  the  known  soluble
modulators secreted by PMN, appear to be important
for a host’s response.2,3
IL-6 plays a key role in inducing and maintaining
inflammatory responses.3 On the contrary, IL-6 acts
also as an anti-inflammatory mediator through down-
regulation of pro-inflammatory cytokines, such as IL-
1b and TNF-a, and simultaneous induction of the IL-1
receptor  antagonist  and  the  soluble  p55  TNF-a
receptor expression.4
The  receptor  complex  mediating  the  biological
activities  of  IL-6  consists  of  two  membrane-bound
proteins, an 80-kDa ligand binding subunit (IL-6R) and
a gp130-kDa signal-transducing subunit.5 Both the IL-
6R and gp130 receptors exist in a soluble form.
The  soluble  IL-6Ra,  which  lacks  the  transmem-
brane  and  cytoplasmic  parts,  is  generated  through
proteolytic  shedding  of  a  membrane-anchored pro-
tein (PC-sIL-6R isoform) or released as a product of
alternative mRNA splicing (DS-sIL-6R isoform).2,6
In contrast to the most soluble cytokine receptors,
sIL-6R exerts agonistic activity when complexed with
its  ligand.  It  is  known  that  sIL-6R  might  act  as  a
regulator  in  a  wide  variety  of  both  normal  and
abnormal biologic reactions. The complex sIL-6R/IL-6
is capable of activating cells through interaction with
membrane-bound  gp130.  By  means  of  this  mecha-
nism, sIL-6R might render IL-6-responsive cells, which
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is a carrier protein for its IL-6 ligand, prolonging the
plasma half-life of IL-6.5,6
It  has  recently  been  shown  that  soluble  IL-6
receptor alone could be an effective stimulator of the
cell function.7,8 Modur et al. demonstrated that PMN
exposed to fMPL shed IL-6R in sufficient quantities to
activate  the  inflammatory  response  of  endothelial
cells.7
The key question of the present study is whether
the sIL-6Ra released by PMN can also influence the
cytokine secretion by peripheral blood mononuclear
cells  (PBMC),  which  together  with  neutrophils
develop the inflammatory and immune response of a
host. Since IL-6 and TNF-a co-stimulate each other’s
release  and  IL-6  is  one  of  the  most  efficient  mod-
ulators of TNF-a production, we examined the effect
of  sIL-6R  and sIL-6R  with IL-6  secreted by PMN on
TNF-a expression and its production by PBMC. Our
studies of the biological function of sIL-6R and IL-6
secreted by PMN may provide new data on the early
phase of inflammation and immune response medi-
ated by these cells.
Material and methods
Cells were isolated from heparinized (10U/ml) whole
blood of 12 healthy persons by Gradisol G gradient
(1.115g/ml). This method enables the simultaneous
separation of two highly purified leukocyte fractions:
PBMC containing 95% lymphocytes, and polymorpho-
nuclear cells cont. 94% PMN. The purity of isolated
PMN  was  determined  by  May-Grunewald-Giemsa
staining.  The  cells  were  washed  three  times  with
RPMI  1640  medium  (Gibco,  Paisley,  Scotland)  and
suspended in the culture medium to provide 5 ´ 106
cells/cm3. The  culture  medium  consisted  of  RPMI
1640  medium  supplemented  with  10%  autologous
serum  (Pro Animal, Wroclaw,  Poland),  100U/ml  of
penicillin and 50ng/ml of streptomycin.
The PMN were cultured in flat-bottomed, 96-well
plates (Falcon, Franklin Lakes, USA) for 1h at 37°C in
a  humidified  incubator  with  5%  CO2 (Nuaire™,
Minnesota,  USA).  After  1h  incubation,  the  culture
supernatant of PMN was removed and added to PBMC
(5 ´ 106 cells/cm3). The viability of PMN was > 92% as
determined by trypan blue exclusion. The PBMC were
cultured for 1h at 37°C in the same conditions. PBMC
with  the  culture  supernatants  of  PMN  and  mono-
clonal antibodies anti-sIL-6R (20ng/ml) and anti-IL-6
(20ng/ml) were the negative control, whereas PBMC
with  recombinant  human  (rh)  sIL-6R  (Endogen,
Woburn,  USA)  and rhIL-6 (R&D,  Minneapolis, USA)
were the positive control.
In the culture supernatants and lysates of PMN, we
examined the concentrations of sIL-6R by the human
sIL-6R  enzyme-linked  immunosorbent  assay  (ELISA)
(Biosource, Nivelles, Belgium).
TNF-a was measured at  both protein and  mRNA
levels. Protein levels were determined by the Human
TNF-a ELISA (Biosource). To examine TNF-a mRNA
expression,  we  isolated  mRNA  from  PBMC  after
culture, using TRIZOL Reagent (Gibco), according to
the manufacturer’s instruction. The quantity of mRNA
TNF-a was determined by the Quantikine mRNA assay
(Base Kit, Quantikine mRNA Probes and Calibrator Kit
– Human TNF-a; R&D Systems).
The concentration of RNA samples was determined
at A260 and A280 using absorbance values in the linear
range of the spectrophotometer. The A260/A280 ratio
for RNA samples was 1.8–1.9.
Results
TNF-a mRNA in PBMC
In  the  PBMC,  after  the  culture  with  PMN  super-
natants, we found a lower expression of TNF-a mRNA
than  in  PBMC  cultured  without  supernatants  from
PMN (Fig.  1). Anti-sIL-6R alone and anti-sIL-6R with
anti-IL-6 monoclonal antibodies were used to confirm
whether the actions of PMN supernatant were gen-
erated by these proteins. In the presence of anti-sIL-
6R antibodies alone, the expression of TNF-a mRNA in
PBMC  cultured  with  PMN  supernatants  was  not
changed. In contrast, in the presence of anti-sIL-6R
with anti-IL-6 monoclonal antibody, the expression of
TNF-a mRNA in PBMC was higher than in the PBMC
cultured without PMN supernatants (Fig. 1A).
We  examined TNF-a expression  in  PBMC  in  the
presence  of  rhsIL-6R alone  and  in  the  presence  of
rhsIL-6R with rhIL-6 to confirm the observations just
mentioned. A similar expression of TNF-a mRNA was
found  in  PBMC cultured  without  PMN supernatant
and  PBMC  cultured  with  rhsIL-6R  alone.  In  the
presence  of  rhsIL-6R  and  rhIL-6,  the  expression  of
TNF-a mRNA  in  PBMC  was  lower  than  in  PBMC
cultured without PMN supernatant.
TNF-a concentrations in the culture
supernatants of PBMC
TNF-a concentrations in the culture supernatants of
PBMC cultured in the presence of PMN supernatants
were lower than those in the supernatants of PBMC
cultured without PMN supernatants (Fig. 1B).
The presence of anti-sIL-6R antibody in the culture
of PBMC with PMN supernatants induced the same
level  of TNF-a secretion as in  the culture of PBMC
alone. In the presence of anti-sIL-6R with anti-IL-6, the
concentration of TNF-a in the PBMC supernatant was
higher  than  in  the  culture  supernatant  of  PBMC
cultured with PMN supernatant. We stimulated PBMC
with  rhsIL-6R  alone  and  rhsIL-6R  with  rhIL-6  to
confirm  the  effect  of  these  mediators  secreted  by
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tions of TNF-a in the culture supernatants of PBMC
with rhsIL-6R were no changed. The secretion of TNF-
a by PBMC in the presence of rhsIL-6R with rhIL-6
was  lower  than  secretion  by  PBMC  without  PMN
supernatant.
Discussion
Soluble  forms  of  receptors are  known  to  be  more
general  phenomena  and  may  play  a  wider  physio-
logical role in the regulation of the immune system
than recognized previously.2
IL-6 on TNF-a expression
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FIG. 1. TNF-a expression and its production by unstimulated and stimulated PBMC. (A) TNF-a mRNA expression (mmol/ml) and
(B) TNF-a concentration in the culture supernatant of PBMC (pg/ml). * Statistical difference with unstimulated PBMC (p < 0.05),
astatistical difference with PBMC cultured with PMN supernatant and anti-sIL-6R and anti-IL-6 (p < 0.05).The results obtained indicate that sIL-6R with IL-6
secreted by PMN belong to the factors responsible for
the TNF-a expression and its production by  autolo-
gous  PBMC.  Joyce  et  al. showed that induction  of
PMN can lead to synthesis of other cytokines, such as
IL-1, granulocyte-macrophage colony-stimulating fac-
tor or TNF-a, which have also been demonstrated to
induce the TNF-a production by mononuclear cells.9
There are different data referring to the biological
activity  of  sIL-6R  alone  or  complexed  with  IL-6.
Modur et  al. found  that sIL-6R  did not  require  the
addition of exogenous IL-6 to the surface expression
of  E-selectin, intracellular  adhesion molecule-1,  vas-
cular cell adhesion molecule-1 and the synthesis of IL-
8 and IL-6 by these cells.7 However, our observations
suggest that sIL-6R alone does not exert an effect on
TNF-a expression in PBMC.
The observations referring to the sIL-6R  and IL-6
function seem to be similar to the other’s results and
appear  to  confirm  the  inhibitory  inter-relations
between IL-6 and TNF-a.8,10 Schindler et al. reported
that  IL-6  suppressed  TNF-a production  by  human
blood mononuclear cells.11 Oh et al. demonstrated
that the IL-6/sIL-6R complex inhibited TNF-a-induced
vascular  cell  adhesion  molecule-1  expression,
whereas it did not affect intracellular cell adhesion
molecule-1 expression.8
There  are  available  data  indicating  that  IL-6  and
TNF-a can be modulated by their soluble receptors
and vice versa.4,6 For example, IL-6 has been found as
a stimulator of soluble TNFRp55 receptor secretion.
This receptor retains the capacity of binding TNF and
may  directly neutralize or modulate TNF activity as
well as possibly indirectly influencing the IL-6 func-
tion.10 Igaz et al. described the inhibiting action of
the sIL-6R/IL-6 on the TNF-a secretion but not on the
mRNA TNF-a expression  by  Jurkat  cells. They  also
found that sIL-6R alone did not influence the TNF-a
production by these cells.12
However, little is known about the biological role
of  a  second  IL-6  soluble  receptor,  sgp130,  also
secreted by PMN and PBMC. Soluble gp130 has been
shown to bind the bio-active IL-6/IL-6R complex and
to inhibit its function.6,13 In our earlier studies, we
demonstrated the ability of PMN to release sgp130 at
a 10-fold higher level than sIL-6R.14The presence of
the relatively large amount of sgp130 in the culture
medium may affect differently the biological function
of  sIL-6R. The  presence  of  sgp130,  inhibiting  IL-6
activity  in  the  culture  supernatants  of  PMN  in  a
paracrine fashion as well as of PBMC in an autocrine
fashion, may be directly responsible for the modula-
tion of TNF-a expression and its production by PBMC.
Moreover, the recent data of Mueller-Neuwen et al.
indicate that sIL-6R enhances the antagonistic effect
of sgp130 and that this effect is more pronounced at
higher  concentrations of  IL-6,  sIL-6R  and sgp130.15
Furthermore,  the  role  of  both  isoforms  of  sIL-6R
produced by PMN in the immune response should be
considered when determining the properties of sIL-
6R.  It  is  known  that  the  PC-sIL-6R  and  DS-sIL-6R
isoforms may independently contribute to the action
of  this  receptor.6 In  the  present  examinations,  we
derived the sIL-6R from the conditioned medium of
PMN  within  60min.  The  sIL-6R  obtained  in  these
examinations may be the PC-sIL-6R isoform that can
be  detected  within  the  first  30–120min  of
stimulation.6
In  conclusion,  the  results  obtained revealed  that
sIL-6R with IL-6 secreted by human PMN may play a
regulatory  function  in  the  immune  response  by
modulating the TNF-a expression and its production
by  PBMC. Decreased TNF-a expression and its pro-
duction by sIL-6R and IL-6-stimulated PBMC may have
a  significant  influence  on  an  early  phase  of  the
inflammation,  mediated by TNF-a.8,10 The data pre-
sented can form  a base for clinical  research in  the
course of infections, in which IL-6 and TNF-a, as well
as their soluble receptors, play a key role.
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